All parties in the French health care system need to prepare themselves for change, as government health care cost controls will be aimed at both patients and physicians. There will also be significant impact on the volume of drugs consumed, according to a new report from Datamonitor - Customer Paradigms: The New Decision Makers - which is available through the offices of the Pharma Marketletter (priced at $2,995); reports are also available on the UK, Italy, Germany and Japan.
The French government is set to become the most powerful decision-maker in the French market as it takes an increasingly interventionalist role in both the volume and the pricing of pharmaceuticals.
In the past, both physicians and patients have enjoyed a great freedom of choice within the French health care system, says Datamonitor. Physicians have had few, if any, budgetary restraints, and patients have been free to consult any physician with unlimited frequency. But this freedom of choice is now being reduced in order to cut costs. All the measures are aimed at reducing the unnecessary consultations and prescribing which currently occur with such regularity in France.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze